NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences announced that its board has approved a share repurchase plan on Thursday, December 7th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Edwards Lifesciences Corp (NYSE:EW) posted its quarterly earnings data on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.11. The medical research company earned $938 million during the quarter, compared to the consensus estimate of $936.69 million. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.94 EPS. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

18 analysts have issued 12-month price objectives for Edwards Lifesciences' stock. Their predictions range from $115.00 to $180.00. On average, they anticipate Edwards Lifesciences' stock price to reach $149.3333 in the next twelve months. View Analyst Ratings for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 5,610,181 shares, an increase of 62.3% from the April 30th total of 3,456,057 shares. Based on an average daily volume of 1,266,171 shares, the short-interest ratio is currently 4.4 days. Approximately 2.7% of the shares of the company are short sold. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), Halyard Health (HYH), CONSORT Med PLC/S (CSRMY), Invacare (IVC), Sientra (SIEN) and RTI Surgical (RTIX).

Media coverage about EW stock has been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.43%), American Century Companies Inc. (1.32%), Northern Trust Corp (1.13%), Wells Fargo & Company MN (1.06%), Disciplined Growth Investors Inc. MN (0.98%) and Massachusetts Financial Services Co. MA (0.97%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., WCM Investment Management CA, Sei Investments Co., Blair William & Co. IL, DekaBank Deutsche Girozentrale, Envestnet Asset Management Inc., Schroder Investment Management Group and Swiss National Bank. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., OppenheimerFunds Inc., Rockefeller Capital Management L.P., Royal Bank of Canada, Chicago Capital LLC, Prudential Financial Inc. and Country Trust Bank. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $149.65.

Edwards Lifesciences has a market capitalization of $32.22 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]